benzinga.comRegeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data3 days ago
benzinga.comFDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls2 months ago
benzinga.comWith Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?3 months ago
finance.yahoo.comJohnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCBabout 1 year ago
benzinga.comargenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024about 1 year ago
CashuArgenx SE (ARGX) Reports Positive Vyvgart Trial Results for Autoimmune Treatment in gMGabout 9 hours ago
CashuArgenx SE: Analyst Sentiment Highlights Opportunities and Challenges in Biotechnology Sector1 day ago